U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Considerations for the Development of Dried Plasma Products Intended for Transfusion
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Considerations for the Development of Dried Plasma Products Intended for Transfusion Guidance for Industry December 2019

Final Level 1 Guidance
Docket Number:
FDA-2018-D-3759
Issued by:
Guidance Issuing Office
Center for Biologics Evaluation and Research

We, FDA, are providing recommendations intended to assist manufacturers, sponsors, and applicants developing dried plasma products intended for transfusion in order to facilitate the availability of safe and effective dried plasma  products in the United States (U.S.).  This guidance provides considerations for the successful development and licensing of dried plasma products and for the approval of devices used to manufacture dried plasma.  The guidance includes recommendations on optimal sources of input plasma;  manufacturing and product quality, including product characterization; packaging and reconstitution; clinical studies; and device submissions.  This guidance finalizes the draft guidance of the same title dated October 2018.

 


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2018-D-3759.

Questions?

Back to Top